AstraZeneca

Wainua launched at only $45M in 2024 but targets hATTR cardiomyopathy — a massively underdiagnosed condition. As cardiac MRI and genetic testing improve, diagnosis rates are expanding 20-30% annually. The addressable market could be 300K+ patients globally vs ~50K currently diagnosed. Wainua is subQ monthly (self-administered) vs Onpattro IV. At $2B peak consensus, the market prices modest penetration — but if diagnosis doubles, so does the TAM. The $80B 2030 revenue target requires multiple drugs hitting peak, and Wainua could be a stealth contributor.

hATTR-CM has multiple competitors (Onpattro, Amvuttra, tafamidis/Vyndaqel). Vyndaqel is $4B+ and entrenched. Wainua needs to prove superiority on cardiac outcomes to displace. The market may fragment rather than expand.

AZN is extending the EGFR franchise with combos (Tagrisso + chemo in FLAURA2, Tagrisso + amivantamab). Even post-LOE, branded combinations maintain value. Pipeline depth provides offset.

Tagrisso is $6.2B and the foundation of AZN's EGFR franchise. Generic osimertinib will be devastating — potentially 70-80% erosion. The combo strategy extends revenue but at higher COGS and marketing expense. The $80B 2030 target has limited margin for Tagrisso erosion. If the cliff hits harder than expected (2028-2029 timeframe), the entire 2030 target becomes unreachable.